science
Biohaven's Clinical Data On BHV-1530, A Novel FGFR3-Directed ADC With A Proprietary Topoisomerase I (Topoix) Payload, Selected For Oral Presentation At The EORTC-NCI-AACR Symposium 2026

(MENAFN - PR Newswire) Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular ...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
ROI & HILM 2027: Verisma Leads Black Book Rankings
Menafn

Edge AI Market Size, Share, Growth, Analysis, Report, 2034
Menafn

Sweden Opens Travel Agency For Introverts
Menafn
APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
Menafn

French Minister Visits ILBS, Boosts Indo-French Research Collaboration
Menafn